Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma

Next Previous
Search
Trial Profile

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naratuximab emtansine (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Debiopharm; ImmunoGen

    • Most Recent Events

    • 09 May 2024 Study design is changed from single group assignment to parallel and sequential. Number of treatment arms are increased from 1 to 5 by the addition of separate arms for Part 1 comprising Cohorts 1 and 2 and Part 2/3 comprising Cohorts A and B.
    • 07 Jun 2022 Results (n=47) of DL analysis using data from this trials to extract spatial features from digitized slides stained with CD37 and CD20 and their predictive role presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2022 According to a Nucleai media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top